**Purpose:** *Chlamydophila pneumoniae* infection in the airways is thought to be associated with the pathogenesis of asthma, especially in non-atopic severe asthma with irreversible airway obstruction that may be related to airway remodeling. Here, we investigated whether *C. pneumoniae* infection enhances the secretion of critical chemical mediators for airway remodeling, such as VEGF, TGF-β, and TIMP-1, in human bronchial epithelial cells (BECs) in a Th2-dominant microenvironment.

**Methods:** Human bronchial epithelial cells (BEAS-2B cells) were infected with *C. pneumoniae* strain TW183 and cultured in both a Th1-dominant microenvironment with INF-γ and a Th2-dominant microenvironment with IL-4 or IL-13 added to the culture medium. The VEGF, TGF-β, and TIMP-1 levels in the culture supernatants were measured using enzyme-linked immunosorbent assays (ELISA). The activation of NF-κB in each experimental condition was determined using an electrophoretic mobility shift assay.

**Results:** *Chlamydophila pneumoniae*-infected BECs showed enhanced secretion of VEGF, TGF-β, and TIMP-1 compared with non-infected BECs. The levels of cytokines secreted from BECs were increased more when IL-13 was added to the culture medium. *C. pneumoniae*-infected BECs also showed increased NF-κB activation.

**Conclusions:** These results suggest that *C. pneumoniae* may play a role in the pathogenesis of airway remodeling in asthma, revealing a Th2-dominant immune response. Further studies are required to clarify the precise mechanism of *C. pneumoniae* infection in airway remodeling.

**Key Words:** Asthma; *Chlamydophila pneumoniae*; epithelial cells; vascular endothelial growth factor A; tissue inhibitor of metalloproteinases; transforming growth factor beta

**INTRODUCTION**

*Chlamydophila pneumoniae* is a widespread respiratory pathogen that may cause acute and chronic respiratory tract illness.1,2 Recently, *C. pneumoniae* infection has emerged as one of the important factors in the pathogenesis of asthma because this organism has been reported to be associated with chronic asthma and its severity,3,5 acute exacerbation,6,7 and even the development of late-onset asthma in both adults and children.8 In addition, a striking association between *C. pneumoniae* infection and persistent airflow limitation has been suggested in longitudinal and cross-sectional sero-epidemiologic studies.10,11

*Chlamydophila pneumoniae* can infect and then reside and replicate in various structural cells including smooth muscle cells, fibroblasts, endothelial cells, bronchial epithelial cells (BECs), and various immune cells. Infection of various cell types with *C. pneumoniae* induces the increased release of many pro-inflammatory chemical mediators, including tumor necrosis factor alpha (TNF-α), interleukin (IL)-8, IL-6, and basic fibroblast growth factor (bFGF), and upregulates adhesion molecules.12,14 In addition, a recent study suggested that *C. pneumoniae*-induced inhibition of apoptosis increases the longevity of the host cell, enhancing the survival of *C. pneumoniae* itself.15 *C. pneumoniae* infection can stimulate the production of IL-10, which can downregulate the expression of major histocompatibility complex class I molecules,16 and it might partially contribute to the resistance to apoptosis and persistence of infected
cells. Furthermore, we previously demonstrated that *C. pneumoniae* enhanced the proliferation of human peripheral blood mononuclear cells and reduced their steroid responsiveness via a TNF-α-dependent pathway.17

Bronchial epithelial cells (BECs) are a first line of defense in viral and bacterial infection. Growing evidence suggests that epithelial cells actively contribute to the pathogenesis of bronchial asthma through the secretion of chemoattractants and pro-inflammatory mediators, which play an important role in the initiation and perpetuation of airway inflammation. Previous studies demonstrated that *C. pneumoniae* can act as a warning system for local immune cells, and airway inflammation can be induced via the *C. pneumoniae*-induced release of various pro-inflammatory cytokines from BECs.16,19 Recently, we demonstrated that *C. pneumoniae*-infected BECs enhanced the secretion of CCL20 and VEGF involved in oxidative stress.20 Taken together, these findings suggest that chronic airway *C. pneumoniae* infection could lead to persistent airway inflammation and may be involved in the airway remodeling observed in the asthmatic airway.

Nevertheless, the exact pathophysiological role of *C. pneumoniae*-infected BECs in the processes of airway remodeling in asthma remains unclear. This study evaluated the effect of *C. pneumoniae* infection on the secretion of important chemical mediators of airway remodeling, such as vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β), and tissue inhibitor of metalloproteinase (TIMP-1) in human BECs in a Th2-dominant microenvironment.

MATERIALS AND METHODS

Culture and inoculum preparation of *Chlamyphila pneumoniae*

*Chlamyphila pneumoniae* was cultured and prepared as described elsewhere.18,21 In brief, strain TW183 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and propagated in HEP-2 cells (ATCC) grown in Eagle’s minimum essential medium (Sigma, St. Louis, MO, USA) supplemented with 1% nonessential amino acids, L-glutamine (2 mM), 10% fetal bovine serum (FBS), non-essential amino acids, gentamicin (10 mg/L), vancomycin (50 mg/L), amphotericin B (2 mg/L), and HEPES buffer solution (GIBCO BRL Life Technologies, Grand Island, NY, USA, 10 mM). Confluent monolayers were infected with *C. pneumoniae* by centrifuging (750× g, 35°C, 45 minutes) infectious inoculae onto the host cells. The supernatant was replaced by antibiotic-free growth medium containing cycloheximide (1 mg/L, Sigma). Infected cells were cultured in a 37°C, 5% CO₂-saturated humidified incubator for 48 and 72 hours, as previously described.22 In brief, infected cells were fixed with methanol-acetone (1:1) and incubated with antibody to major outer membrane protein (mouse IgG3 anti-*C. pneumoniae* monoclonal antibody (mAb); Dako, Cambridgeshire, UK), followed by fluorescein isothiocyanate (FITC)-conjugated secondary antibody (goat F(ab’)2, anti-mouse IgG; Sigma). After counting *C. pneumoniae* inclusions under a fluorescence microscope and correcting for dilution factors, the bacterial titers were expressed as inclusion-forming units (IFU/cell).

Cell proliferation assay

After confirming *C. pneumoniae* infection with the IF assay, we evaluated whether the cellular proliferation after *C. pneumoniae* infection was maintained and determined the proper incubation time and titer of *C. pneumoniae*. BEAS-2B cells were grown to confluence in 96-well plates and were infected with titers of 0, 0.1, 1, and 10 IFU for 96 hours. Then, 10 μL/well of WST-1 reagent was added to each sample. After a 1-hour incubation in a humidified atmosphere (37°C, 5% CO₂), the optical density of the wells was determined by spectrophotometry at a wavelength of 440 nm. The analysis was performed 12, 24, 48, 72, and 96 hours after the initial infection. The results were expressed as the percentage increase in cellular proliferation calculated based on the colony-forming units of each sample.

Analysis of VEGF, TGF-β, and TIMP-1 production

BEAS-2B cells were infected with *C. pneumoniae* (1 IFU/cell determined in a proliferation assay) by centrifuging and cultured as described above. Cell-culture supernatants were collected and analyzed 24 hours after *C. pneumoniae* infection, and the levels of VEGF, TGF-β, and TIMP-1 were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s guidelines. To evaluate the effect of different microenvironments on the production of cytokines, we added IL-4 (20 ng/mL) or IL-13 (20 ng/mL) for a Th2-dominant
environment and INF-γ (20 ng/mL) for a Th1-dominant environment to the culture medium 30 minutes before C. pneumoniae infection.

Evaluation of NF-κB activation

To investigate whether NF-κB activation is associated with the effect of C. pneumoniae infection on BECs, an electrophoretic mobility shift assay (EMSA) was performed. First, nuclear protein was isolated and prepared using a described method. Briefly, cells were collected with a scraper and washed twice with phosphate-buffered saline. Then, the cell pellet was suspended in buffer A (10 mM HEPES pH 7.8, 15 mM KCl, 2 mM MgCl₂, 1 mM EDTA, 0.5 mM DTT, 1 mM PMSF, 2 µg/mL leupeptin) supplemented with 1% Igepal. After a 15-minute incubation at 0°C, the lysed cellular suspension was briefly mixed on a vortex and microcentrifuged for 30 seconds at 4°C. After removing the supernatant, the cell pellet was resuspended in buffer B (20 mM HEPES pH 7.8, 50 mM KCl, 2 mM MgCl₂, 1 mM EDTA, 20% glycerol, 0.5 mM DTT, 1 mM PMSF, 2 µg/mL leupeptin) for 30 minutes at 4°C. The cellular suspension was microcentrifuged at 14,000 rpm for 30 seconds. Then, the supernatant was collected and stored at -80°C.

The consensus NF-κB oligonucleotide (sense 5’-AGT TGA GGG GAC TTT CCC AGG C-3’, antisense 3’-TCA ACT CCC CTG AAA GGG TCC G-5’) was end-labeled with [γ³²P]ATP using T4 polynucleotide kinase. EMSA binding reactions were performed by incubating 5 µg of nuclear extract with 1 µg of poly (dI:dC) in a binding reaction mixture (100 mM HEPES, pH 7.8, 60 mM KCl, 1 mM EDTA, 7% glycerol, 1 mM DTT) for 30 minutes at 37°C. For the antibody supershift, NF-κB antibodies p50 and p65 were added to each reaction mixture and allowed to bind for 1 hour at 0°C. The reaction mixture was electrophoresed on 6% polyacrylamide gels before vacuum drying and exposure to a storage phosphor screen for quantification and documentation.

Statistical methods

All data are expressed as the mean±SEM. The comparisons were made using the Mann-Whitney U-test. Statistical significance was defined as $P<0.05$.

RESULTS

Identification of C. pneumoniae infection in BECs

To confirm the C. pneumoniae infection in host cells, we identified inclusion bodies (element body, EB) of C. pneumoniae in BEAS-2B cells for 48 hours using an IF assay; most of the cultured cells contained numerous EBs for up to 72 hours (Fig. 1A). Based on the results of the proliferation assay performed to determine the proper incubation time and bacteria titer, the cellular proliferation of cells infected with C. pneumonia at a dose of 1 IFU/cell increased continuously, beginning 24 hours after infection, and reached near-maximal levels 48 hours after infection, whereas the cellular proliferation decreased with higher titers of bacteria and more than 72 hours after infection.

![Fig. 1. C. pneumoniae strain TW-183 in BEAS-2B cells. (A) BEAS-2B cells grown on cover slips were infected with C. pneumoniae. After 24 hr, cells were fixed with methanol, and stained using a fluorescein conjugated, pneumonia IgG-FITC (×200), BEAS-2B cells (red), C. pneumoniae (green). Proliferation effect of BEAS-2B cells infected with C. pneumoniae. (B) BEAS-2B cells were infected with C. pneumoniae at 0 (●), 0.1 (▲), 1 (▼), and 10 (♦) inclusion forming unit (IFU)/cell and cell viability measured at different time points post infection (12, 24, 48, 72, and 96 hr). Results shown are representative of three independent experiments.](image-url)
(Fig. 1B). Therefore, we decided to use 1 IFU/cell and 24 hours after infection as appropriate experimental conditions for further analyses.

**Enhanced secretion of VEGF, TGF-β, and TIMP-1 in C. pneumoniae-infected bronchial epithelial cells**

Compared with uninfected cells, the levels of VEGF, TGF-β, and TIMP-1 in the supernatants of infected BECs were increased significantly. These results were observed not only in the Th1- and Th2-dominant microenvironments, but also under control conditions (Fig. 2). IL-13 further enhanced the production of VEGF and TGF-β from both C. pneumoniae-infected and uninfected BECs, whereas treatment with IL-4 and INF-γ did not have a significant effect on the secretion of those cytokines. By contrast, the secretion of TIMP-1 from both C. pneumoniae-infected and uninfected BECs was higher with the INF-γ treatment.

**NF-κB activation in C. pneumoniae-infected bronchial epithelial cells**

As shown in Figure 3A, the nuclear extracts yielded stronger bands in comparison to the uninfected cells, exhibiting relatively higher levels of NF-κB DNA-binding activity. When the enhanced NF-κB binding was quantified by densitometry, C. pneumoniae infection increased the NF-κB binding under Th1 and Th2 microenvironments. Conversely, INF-γ pretreatment reduced the NF-κB binding activity in uninfected cells (Fig. 3B).

**DISCUSSION**

In this study, we demonstrated that C. pneumoniae-infected BECs significantly enhanced the secretion of VEGF, TGF-β, and TIMP-1, which are thought to be the major cytokines involved in airway remodeling. In addition, the levels of these cytokines were increased further under a Th2-dominant microenvironment. These results suggest that C. pneumoniae infection in the asthmatic airway may be involved in the pathogenesis of airway remodeling.

Bronchial asthma is a Th2-dominant inflammatory airway disease with variable airway obstruction. In some asthmatics, persistent airflow limitation and a decline in lung function have been observed and could be one of the critical factors contributing to severe asthma. It is also thought that structural changes...
in the airways, widely referred to as airway remodeling, are associated with irreversible fixed airway obstruction. The remodeling in the asthmatic airway is characterized by subepithelial fibrosis, increased airway smooth muscle mass, hyperplasia of mucous glands and goblet cells, angiogenesis, and alterations in the extracellular matrix components. Although chronic inflammation is thought to be a key factor contributing to airway remodeling, the precise mechanisms remain poorly understood.

For decades, studies have suggested a strong association between viral or bacterial infection and asthma exacerbations, as well as chronic persistent asthma. *C. pneumoniae* is an obligate intracellular Gram-negative bacterium that infects humans as a respiratory pathogen. *Chlamydophila* has a biphasic life cycle, existing as either an elementary body (EB) or a reticulate body (RB). The metabolically inactive extracellular infectious EB is internalized by the host cell, where it differentiates into the metabolically active RB. Under certain conditions, RBs do not re-differentiate directly into EBs, but form interim non-replicating persistent bodies, allowing the bacterium to maintain a chronic latent infection. Many ongoing studies are investigating the association between *C. pneumoniae* and the pathogenesis of various chronic inflammatory diseases, such as atherosclerosis, macular degeneration, and Alzheimer’s disease.

To our knowledge, this is the first study to investigate the potential role of *C. pneumoniae* infection in enhanced secretion of the cytokines associated with airway remodeling by BECs. Our results demonstrated that *C. pneumoniae*-infected BECs lead to the enhanced secretion of VEGF, TGF-β, and TIMP-1. Although the functions of these cytokines are very diverse, the pivotal features of airway remodeling in asthma, such as enhanced tissue fibrosis, angiogenesis, and hypertrophy of constitutional cells may be attributed to the increased levels of VEGF, TGF-β, and TIMP-1. As a result, another study reported that *C. pneumoniae*-infected BECs released more IL-8 and prostaglandin E2 and expressed more ICAM-1 in a time-dependent manner. It was also suggested that the blocking of bacterial adherence reduced the gene expression of IL-8, INF-γ, and TNF-α in BECs. Collectively, these findings indicate that *C. pneumoniae*-infected BECs may play an important role in the pathogenesis of asthma through enhanced induction of critical chemical mediators.

In this study, *C. pneumoniae*-infected BECs under a Th2-dominant microenvironment secreted more VEGF, TGF-β, and TIMP-1 than did those under control conditions, especially with the addition of IL-13. Considering the possibility of chronic or recurrent airway infection with *C. pneumoniae* in asthmatic patients, infected epithelial cells could produce various additional pro-inflammatory cytokines under a pre-existing Th2-dominant microenvironment. These results are consistent with a report in which Th2 cytokines enhanced TGF-β and VEGF production. In this context, our results showed that the interaction between the Th2 environment and superimposed *C. pneumoniae* infection is more likely to play an important role in airway remodeling.

In this study, the production of TIMP-1 was enhanced after pretreatment with the Th1-derived cytokine INF-γ, although we also saw a tendency toward enhanced TIMP-1 secretion with IL-13 treatment. Previous studies reported that the levels of INF-γ in the blood and sputum of asthmatics were increased and correlated with asthma severity. TIMP-1 is the major inhibitor of matrix metalloproteinase 9 (MMP-9), which has fibrinolytic properties and promotes the growth of fibroblasts and myofibroblasts. Some researchers have reported that an excess
of TIMP-1 over MMP-9 in the bronchial secretions of asthmatic patients is associated with chronic airflow obstruction.\textsuperscript{28,29} Therefore, INF-\(\gamma\)-induced TIMP-1 secretion may be involved in the pathogenesis of severe asthma with fixed airway obstruction, although the clinical and pathophysiological implications and exact mechanisms are not clear. Unfortunately, we did not measure the MMP-9 levels, so it is hard to draw any conclusions regarding the role of TIMP-1 in the association of INF-\(\gamma\) and \textit{C. pneumoniae}. Further studies should investigate the MMP-9 production in \textit{C. pneumoniae} infection and the role of INF-\(\gamma\) during the production of this enzyme.

NF-\(\kappa B\) was activated in \textit{C. pneumoniae}-infected BECs in our study, whereas stimulation with IL-4, IL-13, or INF-\(\gamma\) had no further effect on the level of NF-\(\kappa B\) activation. This increased response of NF-\(\kappa B\) activation to the \textit{C. pneumoniae} infection was consistent with previous studies of vascular endothelial cells and epithelial cells.\textsuperscript{30} Furthermore, the results of a recent study suggested that \textit{C. pneumoniae} triggers a pro-inflammatory signaling cascade involving p38 MARK-dependent NF-\(\kappa B\) activation, resulting in subsequent GM-CSF release.\textsuperscript{31} Nevertheless, the exact mechanism by which \textit{C. pneumoniae} infection induces VEGF, TGF-\(\beta\), and TIMP-1 secretion is still unclear.

Interest is growing in developing strategies for preventing airway remodeling. The search for novel therapeutic agents based on a clear understanding of the pathogenesis of airway remodeling is also intensifying. In fact, some evidence suggests that macrolide antibiotics do have beneficial effect in asthma, although it is not clear whether the benefit is due to the anti-inflammatory or antimicrobial effects of these antibiotics. Our data provide additional evidence that macrolide antibiotic treatment could have beneficial effects on reducing pro-inflammatory cytokines and airway remodeling, especially in asthmatic patients with chronic \textit{C. pneumoniae} infection. Further work focusing on the identification of chronic infection is needed.

In conclusion, our results suggest that \textit{C. pneumoniae}-infected BECs may play a role in the pathogenesis of airway remodeling in asthma under a Th2-dominant microenvironment through enhanced secretion of various cytokines.

**ACKNOWLEDGMENTS**

This study was supported by grants from the Korea Healthcare Technology 21 R&D Project, Ministry of Health, Welfare, and Family Affairs, Republic of Korea (A040153 and A030001).

**REFERENCES**

1. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-25.
2. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995;8:451-61.
3. Cook PJ, Davies P, Tunnicliffe W, Ayres JG, Honeybourne D, Wise R. Chlamydia pneumoniae and asthma. Thorax 1998;53:254-9.
4. Falck G, Gnarpe J, Hansson L-O, Svardsudd K, Gnarpe H. Comparison of Individuals With and Without Specific IgA Antibodies to Chlamydia pneumoniae: Respiratory Morbidity and the Metabolic Syndrome. Chest 2002;122:1587-93.
5. Von Hertzen L, Vasankari T, Liippo K, Wahlström E, Puolakkainen M. Chlamydia pneumoniae and Severity of Asthma. Scand J Infect Dis 2002;34:22-7.
6. Betsou F, Sueur JM, Orfila J. Anti-Chlamydia pneumoniae heat shock protein 10 antibodies in asthmatic adults. FEMS Immunol Med Microbiol 2003;35:107-11.
7. Miyashita N, Kubota Y, Nakajima M, Niki Y, Kawane H, Matsu- mitsa T. Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol 1998;80:405-9.
8. Esposito S, Blasi F, Arosio C, Fioravanti L, Fagetii L, Droghetti R, Tarsia P, Allegra L, Principi N. Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J 2000;16:1142-6.
9. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991;266:225-30.
10. Pasternack R, Huhtala H, Karjalainen J, Chlamydyphila (Chlamydia-ia) pneumoniae serology and asthma in adults: A longitudinal analysis. J Allergy Clin Immunol 2005;116:1123-8.
11. ten Brinke A. Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 2008;8:63-9.
12. Rödel J, Woytas M, Groh A, Schmidt KH, Hartmann M, Lehmann M, Straube E. Production of Basic Fibroblast Growth Factor and Interleukin 6 by Human Smooth Muscle Cells following Infection with Chlamydia pneumoniae. Infect Immun 2000;68:3635-41.
13. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydia and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999;103:571-7.
14. Kaukonanta-Tolvanen SSE, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996;21:215-21.
15. Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat Rev Microbiol 2004;2:802-8.
16. Caspar-Bauguil S, Puissant B, Nazzal D, Lefèvre JC, Thomsen M, Salvayre R, Benoist H. Chlamydia pneumoniae induces Interleukin-10 Production that Down-Regulates Major Histocompatibility Complex Class I Expression. J Infect Dis 2000;182:1394-401.
17. Cho YS, Kim TB, Lee TH, Moon KA, Lee J, Kim YK, Lee KY, Moon HB. Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-\(\alpha\)-dependent pathway. Clin Exp Allergy 2005;35:1625-31.
18. Jahn HU, Krüll M, Wuppermann FN, Kluken AC, Rosseau S, Seybold J, Hegemann JH, Jantos CA, Suttorp N. Infection and activation of airway epithelial cells by Chlamydia pneumoniae. J Infect Dis 2002;186:1678-87.
19. Yang J, Hooper WC, Phillips DJ, Tondella ML, Talkington DF. Induction of Proinflammatory Cytokines in Human Lung Epithelial Cells during Chlamydia pneumoniae Infection. Infect Immun 2003;71:614-20.
20. Kim TB, Moon KA, Lee KY, Park CS, Bae YJ, Moon HB, Cho YS. Chlamydyphila pneumoniae triggers release of CCL20 and vascu-
lar endothelial growth factor from human bronchial epithelial cells through enhanced intracellular oxidative stress and MAPK activation. J Clin Immunol 2009;29:629-36.
21. Cho YS, Kim TB, Lee TH, Moon KA, Lee J, Kim YK, Lee KY, Moon HB. Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-α-dependent pathway. Clin Exp Allergy 2005;35:1625-31.
22. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86:2336-40.
23. Jeffery PK. Remodeling and Inflammation of Bronchi in Asthma and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2004;1:176-83.
24. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial infection. Microbiol Rev 1994;58:686-99.
25. Wen FQ, Liu X, Manda W, Terasaki Y, Kobayashi T, Abe S, Fang Q, Ertl R, Manouilova L, Renmard SI. TH2 Cytokine-enhanced and TGF-β-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-γ and corticosteroids. J Allergy Clin Immunol 2003;111:1307-18.
26. Kim YK, Oh SY, Jeon SG, Park HW, Lee SY, Chun EY, Bang B, Lee HS, Oh MH, Kim YS, Kim JH, Gho YS, Cho SH, Min KU, Kim YY, Zhu Z. Airway Exposure Levels of Lipopolysaccharide Determine Type 1 versus Type 2 Experimental Asthma. J Immunol 2007;178: 5375-82.
27. Magnan AO, Mély LG, Camilla CA, Badier MM, Montero-Julian FA, Guillot CM, Casano BB, Prato SJ, Fert V, Bongrand P, Vervloet D. Assessment of the Th1/Th2 Paradigm in Whole Blood in Asthma. Increased IFN-γ-producing CD8+ T Cells in Asthma. Am J Respir Crit Care Med 2000;161:1790-6.
28. Bosse M, Chakir J, Rouabha M, Boulet LP, Audette M, Laviolette M. Serum Matrix Metalloproteinase-9: Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Steroid Responsiveness in Moderate to Severe Asthma. Am J Respir Crit Care Med 1999;159:596-602.
29. Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena R, Chin K, Mio T, Ito Y, Muro S, Hirai T, Morita S, Fukushima S, Mishima M. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005;60:277-81.
30. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC. Chlamydia pneumoniae Infection of Vascular Smooth Muscle and Endothelial Cells Activates NF-κB and Induces Tissue Factor and PAI-1 Expression: A Potential Link to Accelerated Atherosclerosis. Circulation 1999;100:1369-73.
31. Krüll M, Bockstaller P, Wuppermann FN, Klucken AC, Mühleng J, Schmeck B, Seybold I, Walter C, Maass M, Rosseau S, Hegemann JH, Suttorp N, Hippenstiel S. Mechanisms of Chlamydomphila pneumoniae-Mediated GM-CSF Release in Human Bronchial Epithelial Cells. Am J Respir Cell Mol Biol 2006;34:375-82.